News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ambit Biosciences To Announce Fourth Quarter And Full-Year 2013 Financial Results


3/6/2014 6:27:55 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, March 6, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced it will report fourth quarter and full-year 2013 operational results after closing of the NASDAQ Global Market on Thursday, March 20, 2014.

A conference call hosted by Michael Martino, president and CEO, and other members of senior management will take place on the same day at 5:00 pm EDT (2:00 pm PDT) and will be webcast live on the Ambit website.

To access the live teleconference call, dial 866-436-9172 in the U.S. and 630-691-2760 for international callers. Please specify to the operator that you would like to join the "Ambit Fourth Quarter and Full-Year 2013 Earnings Conference Call," referencing conference ID number 36742362. If you are unable to listen to the live webcast, a teleconference replay will be available through Thursday, March 27, 2014. Interested parties can access the replay by dialing 888-843-7419 and entering the passcode 36742362.

The conference call webcast is accessible through the "Investors & Media" section of the Ambit website at http://www.ambitbio.com. An online replay will be available following the initial broadcast until Thursday, April 24, 2014.

About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

Ambit Contacts:

Marcy Graham

Andrew McDonald, Ph.D.

Executive Director, Investor Relations & Corp Comm

LifeSci Advisors, LLC

Ambit Biosciences Corporation

Founding Partner

858-334-2125

646-597-6987

mgraham@ambitbio.com

andrew@lifesciadvisors.com

SOURCE Ambit Biosciences



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES